Document is current
Any future updates will be listed below
-
Authors
Zang, Weijia
Koike, Yui
Nishimura, Koutarou
Tanaka, Atsushi
Yamazaki, Hiromi
Yamasaki, Takaya
Ito, Hiromi
Zhang, Yifan
Aoyama, Yumi
Saika, Wataru
Xiao, Muran
Hasegawa, Chihiro
Kunimoto, Hiroyoshi
Nakajima, Hideaki
Ishikawa, Fumihiko
Takaori-Kondo, Akifumi
Inoue, Daichi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP23K07824)
Japan Society for the Promotion of Science (JP24H00866)
Japan Agency for Medical Research and Development (JP24ama221135)
Japan Agency for Medical Research and Development (JP23ama221126)
Takeda Science Foundation
Princess Takamatsu Cancer Research Fund
JST CREST (JPMJCR23B7)
Japanese Society of Hematology
Ono Pharmaceutical Foundation for Oncology
Mitsubishi Foundation
Kobayashi Foundation for Cancer Research
Chugai Foundation for Innovative Drug Discovery Science
Foundation for Promotion of Cancer Research
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 18 September 2025
First Online: 23 October 2025
Declarations
:
: D.I. has received prior research funding and venetoclax compounds from Abbvie. No other potential conflict of interest relevant to this article was reported. There are no competing interests of the other authors.
